Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > this is done

<< Previous

Bullboard Posts

Next >>

Comment by WTStockon Mar 01, 2021 5:37pm

150 Views

Post# 32691081

RE:RE:RE:RE:this is done

I'm not attacking if you have skin in the game you shouldn't be posting negative things because new investors or just sell any chance they get
I've been in this stock since October 2017 I have quite a bit of skin in my positions did not hold out this long just to hold for nothing this is the time to stock needs to go up with everything that's going on around the world it is Klays time to shine
And if they have what they say they do it will save thousands and thousands of lives which is a positive for everything considering how the last year has gone

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments